The growth track for Inovio Pharmaceuticals Inc (INO) has changed recently

With 0.53 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.56 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $13.38 whereas the lowest price it dropped to was $12.12. The 52-week range on INO shows that it touched its highest point at $14.75 and its lowest point at $3.89 during that stretch. It currently has a 1-year price target of $19.25. Beta for the stock currently stands at 1.12.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of INO was up-trending over the past week, with a rise of 0.08%, but this was up by 29.95% over a month. Three-month performance surged to 102.78% while six-month performance rose 165.85%. The stock gained 30.54% in the past year, while it has gained 102.78% so far this year. A look at the trailing 12-month EPS for INO yields -6.11 with Next year EPS estimates of -2.96. For the next quarter, that number is -0.99. This implies an EPS growth rate of 36.75% for this year and 23.29% for next year. EPS is expected to grow by 41.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 13.49%.

Float and Shares Shorts:

At present, 23.37 million INO shares are outstanding with a float of 22.98 million shares on hand for trading. On Mar 15, 2024, short shares totaled 2.06 million, which was 8.81% higher than short shares on Feb 15, 2024. In addition to NIO as the firm’s NIO Inc., INO serves as its Inovio Pharmaceuticals, Inc.

Institutional Ownership:

Through their ownership of 17.99% of INO’s outstanding shares, institutional investors have minority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for INO since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, INO has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and INO currently yields $0.00. In the past year, INO’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, INO has a current buyback yield of $––. This was $–– for the TTM, and it was $–– for the past five years.